Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection.
The objective is to explore the clinical curative effects of methylprednisolone combined with MTX and DXM intrathecal injection in treating neuropsychiatric systemic lupus erythematosus (NPSLE) and its effects on autoantibody level and anti-N-methyl-D-aspartate receptor subtype NR2a/2b antibody (anti-NR2 antibody) level. Thirty six admitted NPSLE patients were treated by methylprednisolone combined with MTX and DXM intrathecal injection. Thirty six SLE patients without neuropsychiatric symptoms were selected as non-NPSLE group. Clinical indexes including SLE activity index, erythrocyte sedimentation rate (ESR), cerebrospinal fluid pressure (CSFP), cerebrospinal fluid protein were observed before and after treatment. Autoantibodies including anti-nuclear antibody (ANA), anti-double stranded DNA antibody (anti-dsDNA antibody), anti-extractable nuclear antigen antibody (ENA-Ab) were detected before and after treatment. Enzyme linked immunosorbent assay was used to detect NR2 antibody level before and after treatment in two groups. Upon treatment of methylprednisolone combined with MTX and DXM intrathecal injection, SLE activity index, ESR, CSFP, cerebrospinal fluid protein of 36 NPSLE patients were significantly decreased. Before treatment, positive rates of ANA, anti-dsDNA antibody, and anti-ENA antibody in both NPSLE group and non-NPSLE group had no significant difference. However, positive rate of anti-NR2 antibody in NPSLE group was significantly higher than that of non-NPSLE group. After treatment, positive rates of autoantibodies and anti-NR2 antibody in both NPSLE and non-NPSLE group were significantly decreased. Anti-NR2 antibody can be a screening index of NPSLE, and methylprednisolone combined with MTX and DXM intrathecal injection has significant curative effects and can effectively decrease autoantibody level and anti-NR2 antibody level.
Department of Rheumatology, The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu, Nangang District, Harbin, 150086, China, drwangjingyuan@163.com.
Jingyuan
J
Wang
Yinhuan
Y
Zhao
Jihui
J
Zhang
Hongwei
H
Lei
Guiqi
G
Zhu
Bingbing
B
Fu
D000328:Adult; D001323:Autoantibodies / Q000276:immunology / Q000378:metabolism*; D003915:Dextromethorphan / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D020945:Lupus Vasculitis, Central Nervous System / Q000188:drug therapy* / Q000276:immunology; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008775:Methylprednisolone / Q000494:pharmacology* / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology*; D016896:Treatment Outcome
D001323:Autoantibodies; D016194:Receptors, N-Methyl-D-Aspartate; D003915:Dextromethorphan; D008775:Methylprednisolone; D008727:Methotrexate